Alopecia or hair loss could possibly be a doable facet impact of Ozempic-like GLP-1 receptor agonists, notably semaglutide and tirzepatide, analysis has discovered.
The findings, revealed in The British Medical Journal, present that GLP-1RA customers had been 37 per cent extra prone to develop alopecia than SGLT-2 inhibitor customers — diabetes medicine which goal kidneys to take away further sugar from urine — whereas that they had a 68 per cent greater threat, in comparison with customers of DPP-4 inhibitors.
DPP4-inhibitors are one other class of medicine which block the DPP-4 enzyme and stimulate insulin launch. All of the medicine are prescribed as anti-diabetes therapies.
Researchers, together with these from the US’ College of Pennsylvania, stated that though absolute threat is low, consciousness of the potential impact could assist inform shared remedy choices.
“Use of GLP-1 receptor agonists was related to an elevated threat of non-scarring alopecia (the place hair follicles stay intact, leaving the potential for regrowth) in adults with sort 2 diabetes,” the authors wrote.
Speedy weight reduction is a widely known set off of hair shedding and can even result in iron or zinc deficiencies, which disrupt the hair development cycle, they stated and added hormonal adjustments can also be related.
Nevertheless, additional research are wanted to make clear the underlying mechanisms, the group stated.
Digital affected person knowledge from the College of Pennsylvania Well being System (Penn Medication) was analysed to match charges of alopecia in adults with sort 2 diabetes who began utilizing GLP-1 receptor agonists or different sorts of diabetes medicine together with, SGLT-2 inhibitors and DPP-4 inhibitors.
General, 12,004 sufferers utilizing GLP-1 receptor agonists had been in contrast with 15,221 utilizing SGLT-2 inhibitors and an additional 11,964 GLP-1 customers had been in contrast with 11,233 DPP-4 inhibitor customers between January 2019 and September 2024.
The researchers stated whereas the examine was a rigorous one, primarily based on prime quality knowledge from a big consultant cohort, there are limitations.
For instance, a scarcity of scientific info restricted the group’s capacity to evaluate particulars akin to severity, extent, length and reversibility of alopecia after stopping remedy. Nor can the authors rule out the chance that unmeasured elements could have influenced the outcomes.
“Our findings lengthen earlier anecdotal security indicators and supply extra systematic proof to tell scientific consciousness of this potential antagonistic impact,” they stated.
